AlloVir Inc Ordinary Shares ALVR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALVR is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
-
FINAL ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!
-
ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.
-
ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
-
ALLOVIR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against AlloVir, Inc. and Encourages Investors to Contact the Firm
-
ALVR DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Action – ALVR
Trading Information
- Previous Close Price
- $0.73
- Day Range
- $0.72–0.77
- 52-Week Range
- $0.63–6.12
- Bid/Ask
- $0.74 / $0.78
- Market Cap
- $86.94 Mil
- Volume/Avg
- 572,355 / 784,388
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 112
- Website
- https://www.allovir.com
Comparables
Valuation
|
Metric
|
ALVR
|
TGTX
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.67 | — |
Price/Book Value | 0.59 | 13.21 | 3.10 |
Price/Sales | — | 8.90 | — |
Price/Cash Flow | — | 39.05 | — |
Price/Earnings
ALVR
TGTX
CELC
Financial Strength
|
Metric
|
ALVR
|
TGTX
|
CELC
|
|---|---|---|---|
Quick Ratio | 6.49 | 5.00 | 12.78 |
Current Ratio | 6.61 | 5.92 | 13.43 |
Interest Coverage | — | 2.04 | −12.43 |
Quick Ratio
ALVR
TGTX
CELC
Profitability
|
Metric
|
ALVR
|
TGTX
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −52.75% | 19.44% | −35.57% |
Return on Equity (Normalized) | −66.34% | 54.76% | −49.08% |
Return on Invested Capital (Normalized) | −59.54% | 35.76% | −39.21% |
Return on Assets
ALVR
TGTX
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mnvrcmrvb | Ygkyv | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rdgnfvbx | Qtyqzr | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lwkdcqfl | Hqtcnj | $98.9 Bil | |
MRNA
| Moderna Inc | Kdtdypqc | Ddydx | $39.7 Bil | |
ARGX
| argenx SE ADR | Tzcxpjfsk | Rzwnd | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Njpjkhwk | Vqqc | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zvwyfzq | Ggdwq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vkpmxlf | Xmwvyw | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jmykbdzqz | Jdvzmj | $12.3 Bil | |
INCY
| Incyte Corp | Dgqfwrpn | Msyrp | $11.8 Bil |